fbpx Two easy- and quick-to-administer techniques for detecting preclinical Alzheimer’s disease | Progress In Mind

Two easy- and quick-to-administer techniques for detecting preclinical Alzheimer’s disease

Alzheimer’s disease (AD) is preceded by an asymptomatic (preclinical) phase that may last decades. During this time, therapeutic interventions might prevent or delay progression to dementia. Two innovative easy- and quick-to-administer sensitive techniques that can detect AD before symptoms develop were presented to a large audience at AAIC 2019.

Diagnosing preclinical AD promises to delay or prevent the development of dementia

Current imaging and molecular/cognitive biomarker techniques enabling an asymptomatic diagnosis of AD are expensive, time-consuming and difficult to administer or of limited sensitivity. However, two new techniques that can be carried out quickly and easily at home or in the physician’s office and repeated as necessary promise to change the natural history of AD through effective intervention and monitoring of patients with asymptomatic AD before the neurodegenerative pathology becomes irreversible.

 

Digitization of the classic clock drawing test

Ability to draw a clock face deteriorates with advancing AD until the clock face is almost unrecognizable. This ability is evaluated in the classic clock drawing task using pen and paper. Using a digital pen, however, enables a much more informative analysis of a variety of cognitive features associated with producing the drawing in real-time, including:

  • drawing efficiency
  • information processing
  • motor control
  • spatial reasoning

The DCTClock takes only 2 minutes to complete

This is the basis for the DCTclock described at AAIC 2019.1 Machine learning techniques have been used to derive a composite score of ranging from 0 to 100 based on the data obtained from digital clocks drawn by thousands of individuals in different diagnostic groups.

The clinical potential of the DCTclock was investigated in 159 individuals who were cognitively normal and 24 who had mild cognitive impairment (MCI), and was found to be highly correlated with the Preclinical Alzheimer’s Cognitive Composite (PACC5), which is sensitive to amyloid burden in asymptomatic AD.

The diagnostic discriminability provided by the DCTclock between individuals who were cognitively normal and those with MCI was 37% higher compared to traditional clock scoring methods and comparable to the PACC5.1 However, whereas the PACC5 takes 30 minutes to complete, the DCTClock takes 2 minutes.

 

The Integrated Cognitive Assessment (ICA) — a 5-minute, self-administered, computerized test

The ICA is based on grayscale animal shape recognition and is independent of language, cultural background and education. It targets cognitive domains affected in the initial stages of AD before the onset of memory symptoms and uses artificial intelligence (AI) to analyze high-dimensional clinical and demographic data to continuously improve its predictive power.

Head-to-head studies have been carried out with widely used cognitive assessments in individuals with mild AD, MCI, and cognitive impairment secondary to multiple sclerosis (MS).

The ICA can be accessed by large populations and used as an accurate endpoint

The ICA had convergent validity with other cognitive assessments, and achieved high accuracy in detecting cognitive impairment, discriminating MCI from mild AD with 96% accuracy.2

The ICA:

  • engaged cognitive areas among the earliest affected by tau pathology in asymptomatic AD on functional magnetic resonance
  • strongly correlated with neurofilament light chain protein  and severity of cognitive impairment
  • demonstrated excellent test-retest reliability and no evidence of learning bias3
This satellite symposium was sponsored by AbbVie and presented at AAIC 2019.
References
  1. Rentz D, et al. Abstract 31529. Presented at AAIC 2019, Los Angeles 15 July 2019.
  2. Kalafatis C, et al. Abstract 33652. Presented at AAIC 2019, Los Angeles 15 July 2019.
  3. Khaligh-Razavi S-M, et al. Scientific Reports 2019;9:article no. 1102.
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country